Compare SCWO & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCWO | AMRN |
|---|---|---|
| Founded | 2021 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 342.8M |
| IPO Year | 2022 | 1998 |
| Metric | SCWO | AMRN |
|---|---|---|
| Price | $2.16 | $16.47 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 69.1K | ★ 101.3K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | $215,037.00 | ★ $181,104,000.00 |
| Revenue This Year | $25,798.80 | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $0.16 | $12.96 |
| 52 Week High | $3.60 | $20.90 |
| Indicator | SCWO | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 66.27 |
| Support Level | $2.10 | $13.58 |
| Resistance Level | $2.84 | $17.04 |
| Average True Range (ATR) | 0.18 | 0.78 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 47.95 | 68.08 |
374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.